Impact of substance dependence and dual diagnosis on the quality of life of heroin users seeking treatment

Subst Use Misuse. 2008;43(5):612-32. doi: 10.1080/10826080701204813.

Abstract

In 189 opioid-dependent subjects on methadone maintenance treatment in Barcelona (Spain), we assessed the prevalence of co-occurrence substance use and non-substance-use disorders (dual diagnosis) by the Psychiatric Research Interview for Substance and Mental Disorders [PRISM], and the impact on quality of life (HRQoL) by the SF-12 (PCS-12 and MCS-12 scales). Rates of substance and non-substance-use diagnoses were 59% and 32%, respectively. Mean scores for PCS-12 and MCS-12 were 44.1+/-10.1 and 39.9+/-11.7, without differences by presence or absence of dual diagnosis. Heroin users on methadone treatment showed a high prevalence of dual diagnosis and a very impaired HRQoL.

Publication types

  • Comparative Study
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antisocial Personality Disorder / diagnosis
  • Antisocial Personality Disorder / epidemiology
  • Antisocial Personality Disorder / psychology
  • Borderline Personality Disorder / diagnosis
  • Borderline Personality Disorder / epidemiology
  • Borderline Personality Disorder / psychology
  • Comorbidity
  • Diagnosis, Dual (Psychiatry)
  • Female
  • Health Status*
  • Heroin Dependence / diagnosis*
  • Heroin Dependence / epidemiology
  • Heroin Dependence / prevention & control
  • Humans
  • Male
  • Mental Disorders / diagnosis*
  • Mental Disorders / epidemiology
  • Mental Disorders / psychology
  • Methadone / therapeutic use
  • Patient Acceptance of Health Care / psychology
  • Prevalence
  • Psychiatric Status Rating Scales / statistics & numerical data
  • Quality of Life*
  • Spain / epidemiology
  • Substance Abuse Treatment Centers / statistics & numerical data

Substances

  • Methadone